Енрофлоксацин (ROXACIN) 10% 250мл Callier

ROXACIN

100mg/ml

Fluoroquinolone antibiotic

PHARMACEUTICAL FORM:

Injectable solution

COMPOSITION:

Enrofloxacin 100mg/ml

INDICATIONS:

Treatment of bacterial infections caused by strains

susceptible to enrofloxacin.

Cattle and Pigs:

Respiratory infections caused by Pasteurella spp. or Mycoplasma spp. Alimentary tract infections caused by E. coli

Cattle: Treatment of local signs (inflammation, milk qualit y and yield) associated with peracute/acute mastitis in lactating dairy cattle caused by E. coli

DOSAGE AND ADMINISTRATION ROUTE:

Cattle and pigs:

Respiratory and alimentary infections and secondary

bacterial infections:

Administer 2,5mg of enrofloxacin/kg bw/day for 3 day

s (equivalent to 2.5 ml of ROXACIN/100 kg

bw). This rate may be doubled to 5 mg/kg bw (equival

ent to 5 ml of ROXACIN/100kg bw) for 5

days in case of complicated respiratory disease.

Administration route: cattle – SC, pigs – IM.

Not more than 2.5 ml should be administered at any

one intramuscular injection site. Not more than 10

ml should be administered at any one

subcutaneous injection site

Cattle: E. coli mastitis:

Administer by slow intravenous injection 5mg of enrofloxacin/kg bw (equivalent to 5ml of

ROXACIN/100kg bw) daily for 2 days.

CONTRAINDICATIONS:

Do not use for prophylaxis. Do not use when resista

nce/cross resistance to (Fluoro)quinolones is

known to occur. Do not use in the case of known hyp

ersensitivity to fluoroquinolones or to any of the

excipients.

WITHDRAWAL PERIOD:

Cattle:

Pigs:

Subcutaneous use

Intravenous use

Intramuscular Use

Meat and offal: 10 days Meat and offal: 4 days Meat

and offal: 10 days

Milk: 84 hours (7 milkings) Milk: 72 hours (6 milki

ngs)

PHARMACOLOGICAL PROPERTIES:

Enrofloxacin is bactericidal in action with a conce

ntration dependent activity against a wide range of

Gram positive and Gram negative bacteria and mycopl

asmas. The mechanism of action of the

quinolones relies upon their ability to inhibit bac

terial DNA gyrase, an enzyme responsible for

controlling the supercoiling of bacterial DNA durin

g replication. The fluoroquinolones also possess

activity against bacteria in the stationary phase b

y an alteration of the permeability of the outer

membrane phospholipid cell wall

ROXACIN

100mg/ml

Fluoroquinolone antibiotic

PHARMACEUTICAL FORM:

Injectable solution

COMPOSITION:

Enrofloxacin 100mg/ml

INDICATIONS:

Treatment of bacterial infections caused by strains

susceptible to enrofloxacin.

Cattle and Pigs:

Respiratory infections caused by Pasteurella spp. or Mycoplasma spp. Alimentary tract infections caused by E. coli

Cattle: Treatment of local signs (inflammation, milk qualit y and yield) associated with peracute/acute mastitis in lactating dairy cattle caused by E. coli

DOSAGE AND ADMINISTRATION ROUTE:

Cattle and pigs:

Respiratory and alimentary infections and secondary

bacterial infections:

Administer 2,5mg of enrofloxacin/kg bw/day for 3 day

s (equivalent to 2.5 ml of ROXACIN/100 kg

bw). This rate may be doubled to 5 mg/kg bw (equival

ent to 5 ml of ROXACIN/100kg bw) for 5

days in case of complicated respiratory disease.

Administration route: cattle – SC, pigs – IM.

Not more than 2.5 ml should be administered at any

one intramuscular injection site. Not more than 10

ml should be administered at any one

subcutaneous injection site

Cattle: E. coli mastitis:

Administer by slow intravenous injection 5mg of enrofloxacin/kg bw (equivalent to 5ml of

ROXACIN/100kg bw) daily for 2 days.

CONTRAINDICATIONS:

Do not use for prophylaxis. Do not use when resista

nce/cross resistance to (Fluoro)quinolones is

known to occur. Do not use in the case of known hyp

ersensitivity to fluoroquinolones or to any of the

excipients.

WITHDRAWAL PERIOD:

Cattle:

Pigs:

Subcutaneous use

Intravenous use

Intramuscular Use

Meat and offal: 10 days Meat and offal: 4 days Meat

and offal: 10 days

Milk: 84 hours (7 milkings) Milk: 72 hours (6 milki

ngs)

PHARMACOLOGICAL PROPERTIES:

Enrofloxacin is bactericidal in action with a conce

ntration dependent activity against a wide range of

Gram positive and Gram negative bacteria and mycopl

asmas. The mechanism of action of the

quinolones relies upon their ability to inhibit bac

terial DNA gyrase, an enzyme responsible for

controlling the supercoiling of bacterial DNA durin

g replication. The fluoroquinolones also possess

activity against bacteria in the stationary phase b

y an alteration of the permeability of the outer

membrane phospholipid cell wall